Drug Trial Radar · NCT03082235
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Sep 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Mar 3, 2017
Primary completion
Oct 11, 2017
Study completion Oct 11, 2017
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Mar 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending oral doses of E6742 in healthy adult participants.
Conditions
- Healthy Participants
Interventions
E6742Drug
gelatin capsules
PlaceboDrug
gelatin capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with any serious adverse event and number of participants with any non-serious adverse eventTime frame: from Screening up to Day 7
- Mean maximum observed concentration (Cmax) of E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
- Time at which the highest drug concentration occurs (tmax) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
- Area under the concentration-time curve from zero time to 24 hours postdose (AUC[0-24h]) E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
- Area under the concentration-time curve from zero time to 72 hours postdose (AUC[0-72h]) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
- Area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t]) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
- Area under the concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
- Terminal elimination phase half-life (t1/2) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
- Apparent total clearance following extravascular administration (CL/F) for E6742 in plasmaTime frame: Days 1 to 7
- Apparent volume of distribution at terminal phase (Vz/F) for E6742 in plasmaTime frame: Days 1 to 7
- AUC metabolite to E6742 ratio following molecular weight correction to E6742 equivalents in plasmaTime frame: Days 1 to 7
- Amount of unchanged drug excreted in urine (Ae) for E6742 and the metabolite ER-1132963Time frame: Days 1 to 7
- Renal clearance (CLR)Time frame: Days 1 to 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.